Analgesic effect of Xeomin injection in the scalp on pain intensity in patients with chronic migraine

Comparison of the analgesic effect of Xeomin injection at 10 points of the scalp with injection at 31 points of the scalp on pain intensity in patients with chronic migraine

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200217046523N2

Enrollment

Registered

2020-08-12

Start date

2020-09-21

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic migraine. Migraine

Interventions

Intervention 1: Intervention group 1: Patients in this group will be treated with zeomin injection at 31 points of the scalp according to the protocol of the Food and Drug Administration. These inject

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Having chronic migraine Complaints of headache despite treatment for six months of migraine prophylaxis with antiepileptics, TCAs and beta-blockers Having informed consent of patients to participate in the study

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Having any underlying disease Taking anticoagulants

Design outcomes

Primary

Measure	Time frame
Intensity of pain. Timepoint: Before and one month and two months and three months after the intervention. Method of measurement: By Visual Analogue Scale questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHeliya Hemasian

Esfahan University of Medical Sciences

h.hemasian@med.mui.ac.ir+98 31 3668 0042

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026